antibody to epstein-barr virus deoxyuridine triphosphate nucleotidohydrolase and deoxyribonucleotide polymerase in a chronic fatigue syndrome subset抗体巴尔病毒脱氧尿苷三磷酸nucleotidohydrolase和脱氧核苷酸聚合酶在慢性疲劳综合症的子集.pdfVIP

Antibody to Epstein-Barr Virus Deoxyuridine Triphosphate Nucleotidohydrolase and Deoxyribonucleotide Polymerase in a Chronic Fatigue Syndrome Subset 1 2 2 3 4 A. Martin Lerner *, Maria E. Ariza , Marshall Williams , Leonard Jason , Safedin Beqaj , 5 6 7 James T. Fitzgerald , Stanley Lemeshow , Ronald Glaser 1 Department of Medicine, Oakland University William Beaumont School of Medicine, Rochester, Michigan, United States of America, 2 Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio, United States of America, 3 Center for Community Research, DePaul University, Chicago, Illinois, United States of America, 4 Pathology Inc, Torrance, California, United States of America, 5 Department of Medical Education, University of Michigan School of Medicine, Ann Arbor, Michigan, United States of America, 6 College of Public Health, The Ohio State University, Columbus, Ohio, United States of America, 7 Institute for Behavioral Medicine Research, The Ohio State University, Columbus, Ohio, United States of America Abstract Background: A defined diagnostic panel differentiated patients who had been diagnosed with chronic fatigue syndrome (CFS), based upon Fukuda/Carruthers criteria. This diagnostic panel identified an Epstein-Barr virus (EBV) subset of patients (6), excluding for the first time other similar ‘‘clinical’’ conditions such as cytomegalovirus (CMV), human herpesvirus 6 (HHV6), babesiosis, ehrlichiosis, borreliosis, Mycoplasma pneumoniae, Chlamydia pneumoniae, and adult rheumatic fever, which may be mistakenly called CFS. CFS patients were treated with valacyclovir (14.3 mg/kg q6h) for $12 months. Each patient